Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
Disc Medicine NASDAQ: IRON Chief Executive Officer John Quisel said patient demand for the company's bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150.
Broker hails EnergyPathways' alliance with Siemens
SP Angel's take on EnergyPathways PLC (AIM:EPP) is that the company has landed an important early-stage partner. The £12 million developer has signed a non-binding cooperation agreement with Siemens Energy covering long-duration energy storage, specifically compressed air systems that can soak up excess wind power and release it when needed.
EnergyPathways rises after striking Siemens Energy storage deal
EnergyPathways PLC (AIM:EPP) shares jumped as much as 10% on Wednesday after the company unveiled a partnership with Siemens Energy to develop long-duration energy storage aimed at helping the grid cope with the swings of renewable generation. The AIM-quoted group has signed a non-binding cooperation agreement with the German engineering giant to advance Compressed Air Energy Storage, a technology that uses surplus power to force air into underground caverns, releasing it later to drive turbines when demand is higher.
EnergyPathways strikes Siemens Energy deal on long-duration storage
EnergyPathways PLC (AIM:EPP) has teamed up with Siemens Energy to explore a new generation of long-duration energy storage that could help smooth out the peaks and troughs of renewable power. The company, which is listed on London's junior AIM market, said it had signed a non-binding cooperation agreement with the German engineering group to work on Compressed Air Energy Storage, a system that stores surplus electricity by using it to compress air underground.
MESH project gains traction with Siemens Energy - ICYMI
EnergyPathways PLC (AIM:EPP) CEO Ben Clube talked with Proactive about a new collaboration with Siemens Energy to advance the MESH integrated energy storage project. This marks a significant milestone for the company as Siemens Energy begins feasibility and engineering design work focused on long-duration energy storage and compressed air storage components.
EnergyPathways shares surge 53% on Siemens Energy partnership for MESH project
Shares in EnergyPathways PLC (AIM:EPP) soared as much as 53% in afternoon trading on Monday after the company revealed Siemens Energy will lead a feasibility study for its flagship MESH energy storage project. The MESH project aims to combine offshore hydrogen, compressed air, and gas storage, delivering low- or zero-carbon electricity to the UK grid and enhancing the country's energy flexibility.
EnergyPathways brings on board Siemens Energy to advance UK's largest integrated energy storage project
EnergyPathways PLC (AIM:EPP) has taken a significant step in its drive to become a leader in grid-scale energy storage, announcing Siemens Energy will conduct a feasibility assessment for its flagship MESH project. MESH aims to integrate offshore hydrogen, compressed air, and gas storage to deliver low- to zero-carbon power to the UK grid, supporting the transition to a renewables-driven energy system.
EPP: Searching For Yield And Stability
The iShares MSCI Pacific Ex. Japan ETF (EPP) invests in over 90 companies in developed Pacific markets, excluding Japan, with a 0.48% management fee. This ETF offers a 3.7% dividend yield and lower valuation, making it a safer option against potential sell-offs in growth and tech stocks in 2025-2026. The ETF primarily tracks the MSCI Pacific Ex. Japan Index, heavily weighted in banking, materials, and industrials, which constitute over 60% of the index.
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress
Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024. Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024.
